Reports
Sale
Global Fibromyalgia Treatment Market Share, Size, Trends, Analysis, Growth, Forecast: By Diagnosis Method: Blood Tests; By Drug Class: Antidepressants, Antiepileptics, Muscle Relaxants, Others; By Route of Administration; By Drug Type; By Treatment Channel; By End User; By Distribution Channel; Regional Analysis; Supplier Landscape; 2024-2032
Global Fibromyalgia Treatment Market Outlook
The global fibromyalgia treatment market attained a value of USD 2.82 million in 2023, driven by the increasing awareness about the condition across the globe. The market size is anticipated to grow at a CAGR of 8.1% during the forecast period of 2024-2032 to achieve a value of USD 5.69 million by 2032.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Key Trends in the Market
Fibromyalgia is defined as a musculoskeletal disorder which causes intense pain, fatigue, sleep, mood swings, headache, depression, and memory issues. This disorder increases the pain sensations to the brain and spinal cord. As there is no definitive cure, fibromyalgia treatment is aimed at providing comfort to the patients using medications and specialised drugs. Women are more susceptible to fibromyalgia.
- The increasing prevalence of fibromyalgia, triggered by the sedentary lifestyles led by the working population, genetic predisposition, infections, and traumatic events in lives of people worldwide, is fuelling the fibromyalgia treatment market growth.
- Rising incidences of conditions such as lupus, rheumatoid arthritis, and osteoarthritis are leading to an increase in the number of cases of fibromyalgia, as patients with these conditions are more likely to develop fibromyalgia at some point in their lives.
- Over the forecast period, the anticipated increase in healthcare expenditure across the emerging economies, rising standards of living, and favourable policies of various governments are expected to improve the diagnosis and treatment infrastructure across the healthcare units, increasing the fibromyalgia treatment market size.
Market Analysis
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Based on drug class, the market is segmented into antidepressants, antiepileptic, muscle relaxants, and analgesics, among others. On the basis of distribution channel, the market is classified into hospital pharmacy, retail pharmacy, and online pharmacy, among others. The regional markets for fibromyalgia treatment can be divided into North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa.
The comprehensive EMR report provides an in-depth assessment of the market based on the Porter's five forces model along with giving a SWOT analysis. The report gives a detailed analysis of the following key players in the global fibromyalgia treatment market, covering their competitive landscape and latest developments like mergers, acquisitions, investments and expansion plans.
- Pfizer, Inc.
- Eli Lilly and Company
- Novartis AG
- Allergan plc
- Sun Pharmaceutical Industries Ltd
- Intec Pharma Ltd
- Astellas Pharma Inc
- Prismic Pharmaceuticals, Inc.
- Others
Market Share by Drug Class
The antidepressant segment, based on drug class, accounts for a sizable fibromyalgia treatment market share. Antidepressants are an effective medication which reduces severe depression and feelings of trauma or exhaustion, while preventing their resurgence. Antidepressants are recommended by many doctors or pharmacists as they are safe and well-researched. In addition, these medicines can improve the quality of life by providing energy to carry out various day to day activities, which is expected to contribute to the fibromyalgia treatment market price. Meanwhile, the muscle relaxants segment is expected to witness a steady growth in the forecast period as it helps patients cope with muscle stress and tension.
Market Share by Distribution Channel
As per the fibromyalgia treatment market report, the retail pharmacy segment accounts for a significant share of the market, based on distribution channel. This can be attributed to wider network and easier accessibility of retail pharmacies. Further, retail pharmacies bring greater convenience to people as it is usually available across remote and major locations in both urban and rural areas. Meanwhile, the online pharmacy segment is expected to register a decent growth in the forecast period due to the rising purchasing power and rapid digitalisation in the pharmaceutical and healthcare sector across the emerging economies.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Competitive Landscape
Pfizer, Inc. is a leading pharmaceutical and biotechnology company which produces high-quality medications for the treatment of chronic conditions. It also carries out clinical trials and vaccine development to combat lethal infections. The company was established in the year 1849 and is currently headquartered in New York, United States.
Eli Lilly and Company is a major pharmaceutical company which is headquartered in Indiana in the United States. The company was established in the year 1876 and currently manufactures high-quality medicines. Segments of this company include diabetes solution centre, oncology support centre, and insulin state patient assistance programmes, among others.
Novartis AG is a prominent pharmaceutical corporation which was founded in 1996 and is currently headquartered in Basel, Switzerland. The company caters to the medical demands of patients suffering from oncological, ophthalmology, and neuro conditions, among others. Novartis AG innovates in digital and scientific technologies to transform the treatment infrastructure in order to improve patient health.
Other market players include Allergan plc, Sun Pharmaceutical Industries Ltd, Intec Pharma Ltd, Astellas Pharma Inc, and Prismic Pharmaceuticals, Inc., among others.
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
| Base Year | 2023 |
| Historical Period | 2017-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Diagnosis Method |
|
| Breakup by Drug Class |
|
| Breakup by Route of Administration |
|
| Breakup by Drug Type |
|
| Breakup by Treatment Channel |
|
| Breakup by End User |
|
| Breakup by Distribution Channel |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Fibromyalgia Disease Overview
3.1 Guidelines and Stages
3.2 Pathophysiology
3.3 Screening and Diagnosis
3.4 Treatment Pathway
4 Patient Profile
4.1 Patient Profile Overview
4.2 Patient Psychology and Emotional Impact Factors
4.3 Risk Assessment and Treatment Success Rate
5 Fibromyalgia Epidemiology Analysis
5.1 Epidemiology Overview (2016-2031)
5.2 North America Fibromyalgia Epidemiology (2016-2031)
5.3 Europe Fibromyalgia Epidemiology (2016-2031)
5.4 Asia-Pacific Fibromyalgia Epidemiology (2016-2031)
5.5 Latin America Fibromyalgia Epidemiology (2016-2031)
5.6 Middle East & Africa Fibromyalgia Epidemiology (2016-2031)
6 Global Fibromyalgia Treatment Market Overview
6.1 Global Fibromyalgia Treatment Market Historical Value (2017-2023)
6.2 Global Fibromyalgia Treatment Market Forecast Value (2024-2032)
7 Global Fibromyalgia Treatment Market Landscape
7.1 Fibromyalgia Treatment: Developers Landscape
7.1.1 Analysis by Year of Establishment
7.1.2 Analysis by Company Size
7.1.3 Analysis by Region
7.2 Fibromyalgia Treatment: Product Landscape
7.2.1 Analysis by Diagnosis Methods
7.2.2 Analysis by Drug Class
7.2.3 Analysis by Route of Administration
7.2.4 Analysis by End User
7.2.5 Analysis by Distribution Channel
8 Fibromyalgia Treatment Challenges and Unmet Needs
8.1 Treatment Pathway Challenges
8.2 Compliance and Drop-Out Analysis
8.3 Awareness and Prevention Gaps
9 Cost of Treatment
10 Global Fibromyalgia Treatment Market Dynamics
10.1 Market Drivers and Constraints
10.2 SWOT Analysis
10.3 Porter’s Five Forces Model
10.4 Key Demand Indicators
10.5 Key Price Indicators
10.6 Industry Events, Initiatives, and Trends
10.7 Value Chain Analysis
11 Global Fibromyalgia Treatment Market Segmentation
11.1 Global Fibromyalgia Treatment Market by Diagnosis Method
11.1.1 Market Overview
11.1.2 Blood Tests
11.1.2.1 Complete Blood Count
11.1.2.2 Erythrocyte Sedimentation Rate
11.1.2.3 Cyclic Citrullinated Peptide Test
11.1.2.4 Rheumatoid Factor
11.1.2.5 Thyroid Function Tests
11.1.2.6 Anti-nuclear Antibody
11.1.2.7 Vitamin D
11.1.2.8 Others
11.2 Global Fibromyalgia Treatment Market by Drug Class
11.2.1 Market Overview
11.2.2 Antidepressants
11.2.2.1 Milnacipran
11.2.2.2 Duloxetine
11.2.2.3 Others
11.2.3 Antiepileptics
11.2.3.1 Pregabalin
11.2.3.2 Others
11.2.4 Muscle Relaxants
11.2.5 Analgesics
11.2.6 Others
11.3 Global Fibromyalgia Treatment Market by Route of Administration
11.3.1 Market Overview
11.3.2 Oral
11.3.2.1 Tablets
11.3.2.2 Capsules
11.3.3 Parentals
11.3.3.1 Intravenous
11.3.3.2 Intramuscular
11.3.4 Others
11.4 Global Fibromyalgia Treatment Market by Drug Type
11.4.1 Market Overview
11.4.2 Over the Counter
11.4.3 Prescription
11.4.3.1 Branded
11.4.3.2 Generics
11.5 Global Fibromyalgia Treatment Market by Treatment Channel
11.5.1 Market Overview
11.5.2 Public
11.5.3 Private
11.6 Global Fibromyalgia Treatment Market by End User
11.6.1 Market Overview
11.6.2 Hospitals
11.6.3 Specialty Clinics
11.6.4 Homecare Settings
11.6.5 Others
11.7 Global Fibromyalgia Treatment Market by Distribution Channel
11.7.1 Market Overview
11.7.2 Hospital Pharmacy
11.7.3 Retail Pharmacy
11.7.4 Online Pharmacy
11.7.5 Others
11.8 Global Fibromyalgia Treatment Market by Region
11.8.1 Market Overview
11.8.2 North America
11.8.3 Europe
11.8.4 Asia Pacific
11.8.5 Latin America
11.8.6 Middle East and Africa
12 North America Fibromyalgia Treatment Market
12.1 Market Share by Country
12.2 United States of America
12.3 Canada
13 Europe Fibromyalgia Treatment Market
13.1 Market Share by Country
13.2 United Kingdom
13.3 Germany
13.4 France
13.5 Italy
13.6 Others
14 Asia Pacific Fibromyalgia Treatment Market
14.1 Market Share by Country
14.2 China
14.3 Japan
14.4 India
14.5 ASEAN
14.6 Australia
14.7 Others
15 Latin America Fibromyalgia Treatment Market
15.1 Market Share by Country
15.2 Brazil
15.3 Argentina
15.4 Mexico
15.5 Others
16 Middle East and Africa Fibromyalgia Treatment Market
16.1 Market Share by Country
16.2 Saudi Arabia
16.3 United Arab Emirates
16.4 Nigeria
16.5 South Africa
16.6 Others
17 Regulatory Framework
17.1 Regulatory Overview
17.1.1 US FDA
17.1.2 EU EMA
17.1.3 INDIA CDSCO
17.1.4 JAPAN PMDA
17.1.5 Others
18 Patent Analysis
18.1 Analysis by Type of Patent
18.2 Analysis by Publication year
18.3 Analysis by Issuing Authority
18.4 Analysis by Patent Age
18.5 Analysis by CPC Analysis
18.6 Analysis by Patent Valuation
18.7 Analysis by Key Players
19 Grants Analysis
19.1 Analysis by year
19.2 Analysis by Amount Awarded
19.3 Analysis by Issuing Authority
19.4 Analysis by Grant Application
19.5 Analysis by Funding Institute
19.6 Analysis by NIH Departments
19.7 Analysis by Recipient Organization
20 Clinical Trials Analysis
20.1 Analysis by Trial Registration Year
20.2 Analysis by Trial Status
20.3 Analysis by Trial Phase
20.4 Analysis by Therapeutic Area
20.5 Analysis by Geography
21 Funding and Investment Analysis
21.1 Analysis by Funding Instances
21.2 Analysis by Type of Funding
21.3 Analysis by Funding Amount
21.4 Analysis by Leading Players
21.5 Analysis by Leading Investors
21.6 Analysis by Geography
22 Partnership and Collaborations Analysis
22.1 Analysis by Partnership Instances
22.2 Analysis by Type of Partnership
22.3 Analysis by Leading Players
22.4 Analysis by Geography
23 Supplier Landscape
23.1 Pfizer Inc.
23.1.1 Financial Analysis
23.1.2 Product Portfolio
23.1.3 Demographic Reach and Achievements
23.1.4 Mergers and Acquisitions
23.1.5 Certifications
23.2 AstraZeneca
23.2.1 Financial Analysis
23.2.2 Product Portfolio
23.2.3 Demographic Reach and Achievements
23.2.4 Mergers and Acquisitions
23.2.5 Certifications
23.3 Eli Lilly and Company
23.3.1 Financial Analysis
23.3.2 Product Portfolio
23.3.3 Demographic Reach and Achievements
23.3.4 Mergers and Acquisitions
23.3.5 Certifications
23.4 Abiogen Pharma.
23.4.1 Financial Analysis
23.4.2 Product Portfolio
23.4.3 Demographic Reach and Achievements
23.4.4 Mergers and Acquisitions
23.4.5 Certifications
23.5 Merck Sharp & Dohme Corp.
23.5.1 Financial Analysis
23.5.2 Product Portfolio
23.5.3 Demographic Reach and Achievements
23.5.4 Mergers and Acquisitions
23.5.5 Certifications
23.6 Novartis AG
23.6.1 Financial Analysis
23.6.2 Product Portfolio
23.6.3 Demographic Reach and Achievements
23.6.4 Mergers and Acquisitions
23.6.5 Certifications
23.7 GlaxoSmithKline plc.
23.7.1 Financial Analysis
23.7.2 Product Portfolio
23.7.3 Demographic Reach and Achievements
23.7.4 Mergers and Acquisitions
23.7.5 Certifications
23.8 Zimmer Biomet
23.8.1 Financial Analysis
23.8.2 Product Portfolio
23.8.3 Demographic Reach and Achievements
23.8.4 Mergers and Acquisitions
23.8.5 Certifications
23.9 Johnson & Johnson Private Limited
23.9.1 Financial Analysis
23.9.2 Product Portfolio
23.9.3 Demographic Reach and Achievements
23.9.4 Mergers and Acquisitions
23.9.5 Certifications
23.10 Ampio Pharmaceuticals Inc.
23.10.1 Financial Analysis
23.10.2 Product Portfolio
23.10.3 Demographic Reach and Achievements
23.10.4 Mergers and Acquisitions
23.10.5 Certifications
23.11 Regeneron Pharmaceuticals Inc.
23.11.1 Financial Analysis
23.11.2 Product Portfolio
23.11.3 Demographic Reach and Achievements
23.11.4 Mergers and Acquisitions
23.11.5 Certifications
23.12 Boehringer Ingelheim International GmbH
23.12.1 Financial Analysis
23.12.2 Product Portfolio
23.12.3 Demographic Reach and Achievements
23.12.4 Mergers and Acquisitions
23.12.5 Certifications
23.13 Abbott
23.13.1 Financial Analysis
23.13.2 Product Portfolio
23.13.3 Demographic Reach and Achievements
23.13.4 Mergers and Acquisitions
23.13.5 Certifications
23.14 AbbVie Inc.
23.14.1 Financial Analysis
23.14.2 Product Portfolio
23.14.3 Demographic Reach and Achievements
23.14.4 Mergers and Acquisitions
23.14.5 Certifications
23.15 Astellas Pharma Inc.
23.15.1 Financial Analysis
23.15.2 Product Portfolio
23.15.3 Demographic Reach and Achievements
23.15.4 Mergers and Acquisitions
23.15.5 Certifications
23.16 BioDelivery Sciences International Inc.
23.16.1 Financial Analysis
23.16.2 Product Portfolio
23.16.3 Demographic Reach and Achievements
23.16.4 Mergers and Acquisitions
23.16.5 Certifications
23.17 Crystal Genomics
23.17.1 Financial Analysis
23.17.2 Product Portfolio
23.17.3 Demographic Reach and Achievements
23.17.4 Mergers and Acquisitions
23.17.5 Certifications
23.18 Daiichi-Sankyo Company Limited
23.18.1 Financial Analysis
23.18.2 Product Portfolio
23.18.3 Demographic Reach and Achievements
23.18.4 Mergers and Acquisitions
23.18.5 Certifications
24 Fibromyalgia Treatment Market- Distribution Model (Additional Insight)
24.1 Overview
24.2 Potential Distributors
24.3 Key Parameters for Distribution Partner Assessment
25 Key Opinion Leaders (KOL) Insights (Additional Insight)
26 Company Competitiveness Analysis (Additional Insight)
26.1 Very Small Companies
26.2 Small Companies
26.3 Mid-Sized Companies
26.4 Large Companies
26.5 Very Large Companies
27 Payment Methods (Additional Insight)
27.1 Government Funded
27.2 Private Insurance
27.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
Key Questions Answered in the Report
In 2023, the global market for fibromyalgia treatment reached a value of USD 2.82 million.
The market is anticipated to grow at a CAGR of 8.1% during the forecast period of 2024-2032 to reach a value of USD 5.69 million by 2032.
The increasing prevalence of fibromyalgia, increasing women population, rising health awareness, and increasing diagnosis infrastructure across the emerging economies are the major drivers of the market.
The key trends in the market include the emerging online retail pharmacies, rising standards of living, and favourable policies of the government.
Antidepressants, antiepileptic, muscle relaxants, and analgesics, among others, are the different drug classes included in the market report.
Hospital pharmacy, retail pharmacy, and online pharmacy, among others, are the segments of the market based on distribution channels.
Family genetics, poor lifestyle, improper nutrition, certain infections, and incidences of physical and emotional trauma can lead to fibromyalgia.
Although, a complete cure for fibromyalgia is not yet available, medications and therapeutics can help reduce the symptoms of this condition.
Pfizer, Inc., Eli Lilly and Company, Novartis AG, Allergan plc, Sun Pharmaceutical Industries Ltd, Intec Pharma Ltd, Astellas Pharma Inc, and Prismic Pharmaceuticals, Inc., among others, are the key market players, according to the fibromyalgia treatment market report.
Purchase Options 10% off
Call us
Purchase Full Report
Mini Report
$ 2969
$2699
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Single User License
$ 5499
$4999
-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Five User License
$ 6599
$5999
-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$ 7699
$6999
-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Why Expert Market Research?
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
NEWSLETTER